Search results for "Psychotic"

showing 10 items of 360 documents

Precuneus and insular hypoactivation during cognitive processing in first-episode psychosis: Systematic review and meta-analysis of fMRI studies

2020

Abstract Introduction The neural correlates of the cognitive dysfunction in first-episode psychosis (FEP) are still unclear. The present review and meta-analysis provide an update of the location of the abnormalities in the fMRI-measured brain response to cognitive processes in individuals with FEP. Methods Systematic review and voxel-based meta-analysis of cross-sectional fMRI studies comparing neural responses to cognitive tasks between individuals with FEP and healthy controls (HC) according to PRISMA guidelines. Results Twenty-six studies were included, comprising 598 individuals with FEP and 567 HC. Individual studies reported statistically significant hypoactivation in the dorsolatera…

medicine.medical_specialtyPsychosisElementary cognitive taskPrecuneusAudiologybehavioral disciplines and activities03 medical and health sciences0302 clinical medicineCognitionParietal LobemedicineHumansNeural correlates of consciousnessCognitionGeneral Medicinemedicine.diseaseMagnetic Resonance Imaging030227 psychiatryDorsolateral prefrontal cortexPsychiatry and Mental healthmedicine.anatomical_structureCross-Sectional Studiesnervous systemFrontal lobePsychotic DisordersPsychologyInsulapsychological phenomena and processes030217 neurology & neurosurgeryRevista de Psiquiatría y Salud Mental (English Edition)
researchProduct

The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode ps…

2021

The work was supported by Guarantors of Brain post-doctoral clinical fellowship to DQ; Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; Heisenberg professorship from the German Research Founda- tion (grant no. 389624707) to UR; the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-…

medicine.medical_specialtyPsychosisPopulationNeurosciences. Biological psychiatry. NeuropsychiatryPHENOTYPESILLNESSPsychotic DisorderPredictive markersArticleCellular and Molecular NeuroscienceDEFICIT SYNDROMERisk FactorsFirst episode psychosismedicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.HumansCannabiClinical geneticsGenetic riskVALIDITYeducationSettore MED/25 - PsichiatriaSCHEDULEBiological PsychiatryMETAANALYSISCannabisUTILITYeducation.field_of_studyRisk FactorESQUIZOFRENIAASSOCIATIONCannabis usemedicine.diseaseBIFACTOR MODELPsychiatry and Mental healthPsychotic DisordersINTERRATER RELIABILITYSchizophreniaLinear ModelsSchizophreniaLinear ModelMedical geneticsPolygenic risk scorePsychologyHumanRC321-571Clinical psychology
researchProduct

ReMindCare, an app for daily clinical practice in patients with first episode psychosis: A pragmatic real-world study protocol.

2021

[EN] Aim Despite the potential benefits of e-health interventions for patients with psychosis, the integration of these applications into the clinical workflow and analysis of their long-term effects still face significant challenges. To address these issues, we developed the ReMindCare app. This app aims to improve the treatment quality for patients with psychosis. We chose to study the app in real world and pragmatic manner to ensure results will be generalizable. Methods This is a naturalistic empirical study of patients in a first episode of psychosis programme. The app was purpose-designed based on two previous studies, and it offers the following assessments: (a) three daily questions…

medicine.medical_specialtyPsychosismedia_common.quotation_subjectPsychological interventionIrritabilitysmartphoneMedication Adherence03 medical and health sciences0302 clinical medicineEmpirical researchmental disordersmedicineCIENCIAS DE LA COMPUTACION E INTELIGENCIA ARTIFICIALElectronic Health RecordsHumansadherencepsychosisPsychiatryappBiological Psychiatrymedia_commonFirst episodeE-healthbusiness.industryEarly Intervention in the Real Worldmedicine.diseasePsychosisMental healthMobile Applications030227 psychiatrySadnessPsychiatry and Mental healthPsychotic DisordersAdherenceAnxietye‐healthSmartphonePshychiatric Mental Healthmedicine.symptombusinessApp030217 neurology & neurosurgeryEarly intervention in psychiatry
researchProduct

Mechanism of New Antipsychotic Medications

2003

Antagonism of D 2 -like dopamine receptors is the putative mechanism underlying the antipsychotic efficacy of psychotropic drugs. Positron emission tomographic studies suggest that the antipsychotic effect of dopamine receptor antagonists occurs within a therapeutic window between 60% and 80%(striatal) D 2 receptor occupancy. The incidence of extrapyramidal side effects increases above the 80% threshold. However, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal D 2 -like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. The most likely explanation for this finding is ari…

medicine.medical_specialtyPsychosismedicine.drug_classmedicine.medical_treatmentAripiprazoleAtypical antipsychoticQuinolonesPharmacologyPartial agonistPiperazinesBasal Ganglia DiseasesArts and Humanities (miscellaneous)Dopamine receptor D2Internal medicinemedicineHumansAntipsychoticDose-Response Relationship DrugReceptors Dopamine D2Putamenmedicine.diseaseCorpus StriatumProlactinDopamine D2 Receptor AntagonistsPsychiatry and Mental healthEndocrinologyMechanism of actionDopamine receptorSchizophreniaAripiprazolemedicine.symptomPsychologyAntipsychotic AgentsTomography Emission-Computedmedicine.drugArchives of General Psychiatry
researchProduct

A common role for psychotropic medications: memory impairment.

2002

Summary The psychopathologic profile of mental disorders is very diverse and psychotropic medications used to treat them differ in their chemical structure. Nevertheless, these drugs share these four characteristics: delayed onset of clinical response, not one of them can be said to cure, there is a high number of non-responders, and the mechanism responsible for their therapeutic action is not known. It is hypothesized that the action of psychotropic medications is memory impairment, understanding memory as the trace left in the nervous system not only by individual experiences but also by genetic and epigenetic phenomena. It is suggested that it would be beneficial to translate some resea…

medicine.medical_specialtyPsychotropic DrugsTherapeutic actionMechanism (biology)Mental DisordersDelayed onsetBrainGeneral MedicineModels PsychologicalAntidepressive AgentsAction (philosophy)Research strategiesMemorymedicineCyclic AMPMemory impairmentHumansPsychologyPsychiatryClinical psychologyAntipsychotic AgentsSignal TransductionMedical hypotheses
researchProduct

Short Message Service (SMS)-based strategy to improve antipsychotic adherence in schizophrenia

2011

ObjectivePoor adherence to antipsychotic treatment is a well-recognized challenge among patients with schizophrenia and is associated with increased morbidity and consumption of health care resources.We evaluated the effect of daily Short Message Service (SMS) reminders on patients’ adherence to antipsychotic medication in schizophrenia.MethodsClinically stabilized outpatients with schizophrenia and considered to be poor adherent (at least one affirmative answer of Morisky-Green questionnaire -MAQ) to antipsychotic monotherapy were included in a multicenter, randomized, open-label, controlled trial. Participants were randomized to receive a daily SMS reminder on their cell phone to take the…

medicine.medical_specialtyShort Message Servicebusiness.industrymedicine.medical_treatmentPsychological interventionAntipsychotic treatmentmedicine.diseaselaw.inventionPsychiatry and Mental healthPrimary outcomeRandomized controlled triallawSchizophreniaHealth carePhysical therapyMedicinebusinessAntipsychoticPsychiatryEuropean Psychiatry
researchProduct

O3.1. ASSOCIATION OF EXTENT OF CANNABIS USE AND ACUTE INTOXICATION EXPERIENCES IN A MULTI-NATIONAL SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS AND CON…

2019

Background FEP patients who use cannabis experience more frequent intoxication experiences compared to controls. It is not clear whether this is consequent to patients being more vulnerable to the effects of cannabis use or to their heavier pattern of use. We aimed to determine whether extent of use predicted psychotic-like and euphoric intoxication experiences in FEP patients and controls and whether this differs between groups. Methods We analysed data on lifetime cannabis using patients (n=655) and controls (n=654) across 15 sites from six countries in the EU-GEI study (2010–2015). We used multiple regression to model predictors of cannabis-induced experiences and Factorial ANOVA to dete…

medicine.medical_specialtybusiness.industryAcute intoxicationSample (statistics)Cannabis usePsychiatry and Mental healthMulti nationalOral Abstractspsychosis cannabis psychotic-like experiences intoxicationFirst episode psychosisMedicineAssociation (psychology)businessPsychiatrySettore MED/25 - PsichiatriaSchizophrenia Bulletin
researchProduct

Pulmonary thromboembolism associated with the use of new antipsychotics in a paediatric patient.

2020

medicine.medical_specialtybusiness.industryMEDLINEText miningThromboembolismPediatrics Perinatology and Child HealthmedicineHumansIntensive care medicinebusinessChildPulmonary EmbolismPaediatric patientsAntipsychotic AgentsJournal of paediatrics and child healthReferences
researchProduct

2020

Abstract Background The long-term effectiveness of antipsychotic maintenance treatment after first-episode psychosis (FEP) is contested. In this real-world observational study, we examined how cumulative exposure to antipsychotics within the first 5 years from FEP was associated with the 19-year outcome. Methods Finnish national registers were used to detect all patients who were hospitalized due to non-affective psychosis in the mid-1990s, and who were treatment naïve prior to the inclusion period (N = 1318). Generalized linear models with logit link function were used to estimate how cumulative exposure to antipsychotics within the first 5 years from onset was associated with mortality, w…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCumulative Exposuremedicine.disease030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineSchizophreniaFirst episode psychosisMedicine030212 general & internal medicinebusinessAntipsychoticAssociation (psychology)PsychiatrySchizophrenia Bulletin Open
researchProduct

Effectiveness of Antipsychotic Medication in the Treatment of BPD

2017

IntroductionThough prescription is off-lable, “atypical” or “second-generation” antipsychotics (SGAs) are prevalently given to borderline personality disorder (BPD) patients. They have also been the focus of research on pharmacological agents in BPD in recent years, as the previous version of the relating cochrane systematic review shows.ObjectivesWe are currently updating this cochrane systematic review on pharmacological interventions for BPD. First findings on the up-to-date evidence relating to SGAs will be presented.MethodsWe conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) according to cochrane collaboration standards. Any randomized comparisons o…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentmedicine.diseasePlaceboPersonality disorderslaw.inventionPsychiatry and Mental healthRandomized controlled trialTolerabilitylawmedicineAnxietymedicine.symptomMedical prescriptionPsychiatryAntipsychoticbusinessBorderline personality disorderClinical psychologyEuropean Psychiatry
researchProduct